Valeant/GSK's Anti-Epileptic Potiga Faces Advisory Committee In Mid-August

High rate of adverse event-related dropouts in clinical trials could be a key focus of panel's discussion of ezogabine, also known as retigabine.

More from Archive

More from Pink Sheet